---
schema_version: "secwatch.filing_event.v1"
accession: "0001965040-23-000048"
form_type: "8-K"
ticker: "FTRE"
cik: "0001965040"
company_name: "Fortrea Holdings Inc."
filed_at: "2023-11-29T23:59:59+00:00"
generated_at: "2026-06-07T20:33:37.034083+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Fortrea disputes ACELYRIN claims on HS and PsA trial conduct; stands by data integrity

## Summary
- Fortrea objects to ACELYRIN's implication that its conduct of the Hidradenitis Suppurativa trial impacted outcomes.
- Disputes accuracy of statements about testing processes and who uncovered the third-party programming error in Psoriatic Arthritis trial.
- Sequencing issue isolated to two arms of the PsA trial, unrelated to the HS trial; no patient safety risk per ACELYRIN.
- Third-party programmer not endpoint Clinical (affiliated with Fortrea); cannot be named due to contractual commitments.

## SEC filing metadata
- accession: 0001965040-23-000048
- form_type: 8-K
- ticker: FTRE
- cik: 0001965040
- company_name: Fortrea Holdings Inc.
- filed_at: 2023-11-29T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1965040/000196504023000048/0001965040-23-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1965040/000196504023000048/ftre-20231127.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001965040-23-000048
- JSON: https://secwatch.observer/filing/0001965040-23-000048.json
- Plain text: https://secwatch.observer/filing/0001965040-23-000048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.